Literature DB >> 16249203

Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes.

Adeera Levin1, Ognjenka Djurdjev, John Duncan, Debbie Rosenbaum, Ron Werb.   

Abstract

Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients. This analysis evaluates the association of baseline haemoglobin levels on survival in CKD patients, who are followed by nephrologists, irrespective of glomerular filtration rate (GFR), prior to initiation of renal replacement therapy (RRT) and erythropoietin hormone replacement therapy. Analysis of data from the provincial database (PROMIS, Patient Registration and Outcome Management Information System) in British Columbia, Canada, was undertaken. Records used for the analysis included all CKD patients at first registration: GFR <60 ml/min/1.73 m(2), not yet on dialysis, starting from May 1998 to October 2002, and who had complete data (defined as age and gender, diabetic status, eGFR and Hgb levels). The primary objective of this study was to determine the association of Hgb and survival controlling for eGFR at first registration value, age, gender and diabetic status. Multivariate Cox proportional hazards analysis with time to death as outcome variable was performed. The cohort included 3028 patients: the mean age was 65 years, 28% were diabetic, and the mean eGFR in the cohort was 21 ml/min/1.73 m(2). The cohort is representative of the BC CKD and dialysis population regarding ethnicity: 64% Caucasian, 32% Asian. Median follow-up was 27 months, 1 year survival was 0.92, 2 year survival was 0.85. Hgb at initial registration is a statistically independent predictor of survival (RR = 0.875 for every 10 g/l, 95% CI: 0.835-0.917, P = 0.0001), after adjusting for age, gender, diabetic status and baseline eGFR. Further analysis, controlling for RRT, demonstrated a similar association between Hgb and survival (RR = 0.853 for every 10 g/l, 95% CI: 0.799-0.910, P = 0.0001), after adjusting for above variables. Substantial variation in Hgb values exists at all GFR levels. These findings underscore the importance of evaluating Hgb at all GFR levels, and the need to study the impact of modification of Hgb at different GFR levels on survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249203     DOI: 10.1093/ndt/gfi209

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

1.  Prognosis of CKD patients receiving outpatient nephrology care in Italy.

Authors:  Luca De Nicola; Paolo Chiodini; Carmine Zoccali; Silvio Borrelli; Bruno Cianciaruso; Biagio Di Iorio; Domenico Santoro; Vincenzo Giancaspro; Cataldo Abaterusso; Ciro Gallo; Giuseppe Conte; Roberto Minutolo
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 2.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

Authors:  Luca De Nicola; Francesco Locatelli; Giuseppe Conte; Roberto Minutolo
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

4.  A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.

Authors:  Pablo E Pergola; Gary Gartenberg; Min Fu; Steven Sun; Marsha Wolfson; Peter Bowers
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

5.  Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Authors:  Michio Kuwahara; Syoko Hasumi; Shintaro Mandai; Tomomi Tanaka; Satomi Shikuma; Wataru Akita; Yoshihiro Mori; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2013-12-07       Impact factor: 2.801

Review 6.  Chronic kidney disease, heart failure and anemia.

Authors:  Sean A Virani; Amit Khosla; Adeera Levin
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

7.  Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Authors:  Roberto Minutolo; Paolo Chiodini; Bruno Cianciaruso; Andrea Pota; Vincenzo Bellizzi; Deborah Avino; Sara Mascia; Simona Laurino; Valerio Bertino; Giuseppe Conte; Luca De Nicola
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

8.  Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Authors:  Michelle W Krause; Rasib Raja; Anil Agarwal; Marcia R Silver; Debra Scarlata; Angela Sciarra; Reshma Kewalramani
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 9.  Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia.

Authors:  Xiaofan Hu; Jingyuan Xie; Nan Chen
Journal:  Kidney Dis (Basel)       Date:  2020-12-17

10.  Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia.

Authors:  Neil Boudville; Kalindu Muthucumarana; Charles Inderjeeth
Journal:  BMC Geriatr       Date:  2012-08-03       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.